论文部分内容阅读
目的探讨阿托伐他汀对扩张型心肌病(DCM)合并心力衰竭患者血清肝细胞生长因子(HGF)水平的影响。方法扩张型心肌病合并心力衰竭患者共60例,随机分为常规治疗与加用阿托伐他汀组各30例,治疗4周前后分别查血清HGF浓度和心脏左室收缩末期容积及左室射血分数,同时选择20例正常对照组。结果血清HGF浓度在扩张型心肌病合并心力衰竭患者明显高于正常对照组差异有统计学意义(P<0.01),治疗4周后,阿托伐他汀组左室收缩末期容积减少及左室射血分数提高更显著,但差异无统计学意义(P>0.05)。结论扩张型心肌病合并心力衰竭患者血清HGF水平明显升高,短期阿托伐他汀可降低DCM患者的血清GHF浓度,该作用独立于其降血脂作用并与心功能的改善无关。
Objective To investigate the effect of atorvastatin on serum hepatocyte growth factor (HGF) level in patients with dilated cardiomyopathy (DCM) complicated with heart failure. Methods A total of 60 patients with dilated cardiomyopathy complicated with heart failure were randomly divided into routine treatment and atorvastatin plus 30 cases. Before and after treatment for 4 weeks, serum HGF concentration, left ventricular end-systolic volume and left ventricular ejection fraction Blood score, while selecting 20 cases of normal control group. Results Serum HGF concentration in patients with dilated cardiomyopathy complicated with heart failure was significantly higher than that in the control group (P <0.01). After 4 weeks of treatment, the volume of left ventricular end-systolic volume and left ventricular ejection fraction Blood scores increased more significantly, but the difference was not statistically significant (P> 0.05). Conclusions Serum HGF levels in patients with dilated cardiomyopathy complicated with heart failure are significantly increased. Short-term atorvastatin can reduce the serum GHF concentration in patients with DCM, which is independent of its hypolipidemic effect and has nothing to do with the improvement of cardiac function.